CN1317003C - 治疗高脂血症胶囊及其制备工艺 - Google Patents
治疗高脂血症胶囊及其制备工艺 Download PDFInfo
- Publication number
- CN1317003C CN1317003C CNB2005100431198A CN200510043119A CN1317003C CN 1317003 C CN1317003 C CN 1317003C CN B2005100431198 A CNB2005100431198 A CN B2005100431198A CN 200510043119 A CN200510043119 A CN 200510043119A CN 1317003 C CN1317003 C CN 1317003C
- Authority
- CN
- China
- Prior art keywords
- capsule
- grams
- cattail pollen
- red sage
- sage root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title abstract description 11
- 240000001398 Typha domingensis Species 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 30
- 201000005577 familial hyperlipidemia Diseases 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 14
- 238000005516 engineering process Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 241000756943 Codonopsis Species 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 38
- 239000008280 blood Substances 0.000 abstract description 38
- 208000002193 Pain Diseases 0.000 abstract description 15
- 230000001737 promoting effect Effects 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 208000002173 dizziness Diseases 0.000 abstract description 7
- 208000008589 Obesity Diseases 0.000 abstract description 5
- 235000020824 obesity Nutrition 0.000 abstract description 5
- 230000002936 tranquilizing effect Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 4
- 208000013433 lightheadedness Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 240000007164 Salvia officinalis Species 0.000 abstract 7
- 241000233948 Typha Species 0.000 abstract 7
- 235000005412 red sage Nutrition 0.000 abstract 7
- 240000001341 Reynoutria japonica Species 0.000 abstract 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 2
- 238000003801 milling Methods 0.000 abstract 2
- 208000006083 Hypokinesia Diseases 0.000 abstract 1
- 206010040007 Sense of oppression Diseases 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明蒲参胶囊及其制备工艺，提供了用纯中药治疗高脂血症的血瘀症药剂，本中药制剂由何首乌、蒲黄、丹参八味中药材制成，制备蒲参胶囊的生产方法分为何首乌制粉、众药煎煮稠膏、干燥制粉、制粒干燥和装囊五道工艺，蒲参胶囊配方科学，制备工艺简便，加工成本低廉，口服方便，用于治疗高脂血症的血瘀症，具有活血祛瘀、滋阴化浊、散结止痛、养心安神功效，能有效消除头晕目眩、胸闷不适、胸胁刺痛或胀痛、心悸、体倦乏力与体形肥胖等症状。
Description
所属技术领域
本发明治疗高脂血症胶囊胶囊及其制备工艺属治疗心脑血管疾病药物及其制备工艺，尤其涉及用中药组方治疗高脂血症药物及其制备工艺。
背景技术
高脂血症是血浆脂质浓度超过正常高限时的病症，可见于多种疾病，中医辨证分为痰浊阴遏证、脾肾阳虚证、肝虚阴虚证、阴虚阳亢证、气滞血瘀证，多因体内胆固醇、甘油三脂、低密度脂蛋白与极低密度蛋白增高，高密度脂蛋白下降引起脂质代谢紊乱，血液粘度增大，直接导致高脂血症的形成，其中以血瘀症最为常见，患者症见头晕目眩、胸闷不适、胸胁刺痛，心悸，体倦乏力，或体形肥胖，动则气短，舌尖边有瘀斑，舌质紫暗，脉象细涩，病状发展时可并发高血压、冠心病、脑血栓、动脉硬化等心脑血管病，目前治疗高脂血症是以积极预防和降脂为主，药物多用化学制剂扩张血管治疗，但由于患者体内脂质紊乱未得到调理，血瘀症状未能消失，血脂易反复升高，患者达不到标本兼治，利用中药组方开发用于高脂血症的血瘀症中成药有着广泛的应用市场。
发明内容
本发明的目的是：给高脂血症的血瘀症患者提供配方科学、疗效显著、制备工艺简便的纯中药制剂，达到活血祛瘀、滋阴化浊、散结止痛、养心安神功效，同时达到扩张血管、改善脂质紊乱和降低血液粘度的效果，有效治疗高脂血症的血瘀症，消除患者头晕目眩，胸闷不适，胸胁刺痛或胀痛、心悸、体倦乏力与体形肥胖等症状。
为了实现上述发明目的，本发明所采用的技术方案是：治疗高脂血症胶囊根据高脂血症的血瘀症主要病因病机，以降低血脂为治疗大法，原料中中药材总量为655克，由何首乌135克、蒲黄110克、丹参66克、川芎66克、赤芍66克、山楂66克、泽泻110克、党参36克组成。制备治疗高脂血症胶囊的方法分为何首乌制粉药、众药煎煮稠膏、干燥制粉、制粒干燥、装囊五道工艺，先取何首乌粉碎得细粉药，再将其余七味药每次加5倍量水煎煮二次，每次2小时，合并煎液，滤过，将滤液减压浓缩至相对密度为1.30～1.32(60℃)的稠膏，与何首乌细粉药混勺，干燥后粉碎成细粉，再添加适量80％乙醇制粒，干燥，整粒，装入1000粒1号胶囊得成药。中医学认为高血脂症的血瘀症形成乃阴虚气滞、血瘀脉络，治疗药剂应以活血祛瘀、滋阴化浊为主，在治疗高脂血症胶囊中，何首乌具有养血滋阴、润肠通便功能，主治血虚头昏目眩、心悸、失眠，为平补阴血之良药，能显著降低血浆总胆固醇、胆固醇脂和甘油三脂含量，抑制动脉膜斑块形成和脂质沉淀，从胆固醇的吸收、代谢等多种途径治疗高血脂症；蒲黄具有止血、祛瘀、利尿功能、主治心腹疼痛，临床证明有良好的降低总胆固醇、升高高密度脂蛋白、降低致动脉硬化系数、降低血小板粘附和聚集性作用，同时对血管内皮细胞有保护作用，并能抑制粥样硬化斑块的形成，显著地降低血脂；丹参具有活血祛瘀、养心安神、调经止痛、凉血消痛功能，主治心腹疼痛、癫瘕积聚、热入营血、失眠心烦，煎剂可降低血中和肝中的甘油三脂，丹参素有降低细胞内胆固醇内源性合成及抗氧化酶修饰低密度脂蛋白的作用；川芎具有活血化瘀、行气开郁、祛风止痛功能，主治胸胁疼痛、头痛眩晕、痈疽疮疡，川芎嗪可抑制心肌收缩，扩张血管，降低血压，有显著增加冠脉血流量的作用；赤芍具有清热凉血、活血祛瘀功能、主治痈疽疮疡、瘀滞胁痛，浸膏剂能显著降低血浆总胆固醇、甘油三脂、低密度脂蛋白、极低密度脂蛋白，增高高密度脂蛋白，并可降低血浆过氧化脂质、动脉壁脂质、钙和磷脂及主动脉斑块面积；山楂具有消食积、化瘀滞功能，主治饮食积滞、脘腹胀痛、高脂血症，其水浸膏能显著降低血清总胆固醇含量，并通过增加胆固醇的排泌明显增加血清中高密度脂蛋白；泽泻具有利水渗湿、泄热通淋的功能，主治小便不利、热淋涩痛、水肿胀满、痰饮眩晕，其水煎剂对肥胖有减肥作用和降血脂作用；党参具有健脾补肺、益气生津功能，主治脾胃虚弱、四肢乏力、气血两亏诸症，其煎剂能明显升高血浆皮质酮水平，对脑垂体-肾上腺皮质系统有兴奋和调节作用，能增强机体应激能力和增强机体免疫功能。众药有效成分于一体，共奏活血祛瘀、滋阴化浊、散结止痛、养心安神功效，有效治疗高血脂症的血瘀症。治疗高脂血症胶囊采用何首乌制粉药、众药煎煮稠膏、干燥制粉、制粒干燥、装囊五道简单工艺制成胶囊，制备工艺简单，加工成本低廉，口服方便。
治疗高脂血症胶囊在临床前研究中与功能主治有关的主要药效学试验已证实有显著疗效，并推荐日口服量为每天3次，每次4粒。
本发明的有益效果是：配方科学，制备工艺简便，口服方便，疗效显著，具有活血祛瘀、滋阴化浊、散结止痛，养心安神功效，能有效治疗高脂血症的血瘀症，消除患者头晕目眩、胸闷不适、胸闷刺痛或胀痛、心悸、体倦乏力与体形肥胖症状。
具体实施方案：
1、治疗高脂血症胶囊原料与辅料备用：
①原料药由八味中药组成，其中何首乌135克、蒲黄110克、丹参66克、赤芍66克、山楂66克、泽泻110克、党参36克，按现行中药材饮片标准分别取八味中药材除杂筛净后称量备用。
②辅料为80％乙醇，取适量备用。
2、治疗高脂血症胶囊制备工艺：
①先取何首乌粉碎过100目筛成细粉药备用。
②再取其余七味中药材每次加5倍量水煎煮二次，每次2小时，合并煎液，滤过，把滤液减压浓缩至相对密度为1.30～1.32(60℃)的稠膏备用。
③将备用细粉药与稠膏混拌均匀，80℃以下温度干燥后粉碎，过100目筛成细粉。
④在细粉中添加适量乙醇制粒，干燥，整粒，分装入1000粒1号胶囊中得成药。
Claims (2)
1、一种治疗高脂血症胶囊，其特征是：原料药中药材总量为655克，由何首乌135克、蒲黄110克、丹参66克、川芎66克、赤芍66克、山楂66克、泽泻110克、党参36克组成。
2、如权利要求1所述治疗高脂血症胶囊的制备工艺，其特征是：先取何首乌粉碎得细粉药，再将其余七味药每次加5倍量水煎煮二次，每次2小时，合并煎液，滤过，将滤液减压浓缩至60℃时相对密度为1.30～1.32的稠膏，与何首乌细粉药混匀，干燥后粉碎成细粉，再添加适量80％乙醇制粒，经干燥、整粒，最后装入1000粒1号胶囊得成药。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100431198A CN1317003C (zh) | 2005-08-18 | 2005-08-18 | 治疗高脂血症胶囊及其制备工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100431198A CN1317003C (zh) | 2005-08-18 | 2005-08-18 | 治疗高脂血症胶囊及其制备工艺 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1733154A CN1733154A (zh) | 2006-02-15 |
| CN1317003C true CN1317003C (zh) | 2007-05-23 |
Family
ID=36075909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100431198A Active CN1317003C (zh) | 2005-08-18 | 2005-08-18 | 治疗高脂血症胶囊及其制备工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1317003C (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083212B (zh) * | 2013-02-04 | 2015-08-19 | 苏文清 | 丹参牙膏 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311023A (zh) * | 2001-02-27 | 2001-09-05 | 周文志 | 洗髓阀毛抗栓净血的药物及制备方法 |
| CN1541671A (zh) * | 2003-04-30 | 2004-11-03 | 无锡山禾药业股份有限公司 | 一种治疗心绞痛的药物及该药物的制备方法和应用 |
| CN1546067A (zh) * | 2003-09-15 | 2004-11-17 | 史 忠 | 一种治疗冠心病和心绞痛的中药 |
| CN1593570A (zh) * | 2004-06-30 | 2005-03-16 | 曹琼 | 一种降脂的中药 |
-
2005
- 2005-08-18 CN CNB2005100431198A patent/CN1317003C/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311023A (zh) * | 2001-02-27 | 2001-09-05 | 周文志 | 洗髓阀毛抗栓净血的药物及制备方法 |
| CN1541671A (zh) * | 2003-04-30 | 2004-11-03 | 无锡山禾药业股份有限公司 | 一种治疗心绞痛的药物及该药物的制备方法和应用 |
| CN1546067A (zh) * | 2003-09-15 | 2004-11-17 | 史 忠 | 一种治疗冠心病和心绞痛的中药 |
| CN1593570A (zh) * | 2004-06-30 | 2005-03-16 | 曹琼 | 一种降脂的中药 |
Non-Patent Citations (3)
| Title |
|---|
| 平脂胶囊的质量标准 王晓娟等，第四军医大学学报，第20卷第10期 1999 * |
| 平脂胶囊的质量标准 王晓娟等，第四军医大学学报，第20卷第10期 1999;正交试验法优选平脂胶囊制备工艺 王晓娟等，第四军医大学学报，第21卷第2期 2000 * |
| 正交试验法优选平脂胶囊制备工艺 王晓娟等，第四军医大学学报，第21卷第2期 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1733154A (zh) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102579774B (zh) | 一种用于治疗颈淋巴结核的中药组合物 | |
| CN102078473A (zh) | 一种治疗慢性乙型肝炎的中药制剂及其制备方法 | |
| CN101433654B (zh) | 一种治疗妇女慢性盆腔炎的中药制剂及其制备方法 | |
| CN105031517A (zh) | 一种降三高的铁皮石斛保健茶及其制备方法 | |
| CN104905267A (zh) | 一种决明子降血脂保健口服液及其制备方法 | |
| CN102327452A (zh) | 能够有效治疗痈症初起的中成药及中药汤剂 | |
| CN106376820A (zh) | 一种用于驱胃寒、保护胃黏膜的固体饮料及其制备方法 | |
| CN105194421A (zh) | 一种夏枯草降血脂保健口服液及其制备方法 | |
| CN108310298A (zh) | 一种具有缓解眼疲劳、防治近视的中药组合物及制备方法 | |
| CN105028772A (zh) | 用于降血脂的保健养生茶及其制备方法 | |
| CN101041017A (zh) | 一种内服治疗慢性浅表性胃炎的中药组合物 | |
| CN105943705A (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
| CN104800504A (zh) | 一种治疗肾炎的中药制剂及制法 | |
| CN1317003C (zh) | 治疗高脂血症胶囊及其制备工艺 | |
| CN105999058B (zh) | 鬼针草降脂片 | |
| CN104225275A (zh) | 一种治疗脑血栓的中药组合物及其制备方法 | |
| CN101062335A (zh) | 一种祛黄褐斑的保健品 | |
| CN104338052A (zh) | 治疗脑血栓的中药配方 | |
| CN104587300A (zh) | 用于治疗急性白血病的中药组合物及其制备方法 | |
| CN104435772A (zh) | 含有山楂的用于降血脂的药物组合物 | |
| CN103705639A (zh) | 一种治疗脑积水的中药制剂 | |
| CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
| CN102772665B (zh) | 一种治疗阴虚内热型病毒性心肌炎的中药制剂及其制备方法 | |
| CN100408082C (zh) | 一种治疗肝病的中药 | |
| CN102100814A (zh) | 一种治疗重症哮喘的纳米中药制备及其生产方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU SUZHONG HAIXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: PHARMACEUTIC INST., NO. 4 MILLITARY MEDICAL UNIV. P. L. A. Effective date: 20110221 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710032 NO. 17, CHANGLE WEST ROAD, XI'AN CITY, SHAANXI PROVINCE TO: 225500 NO. 1, SUZHONG ROAD, JIANGYAN CITY, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110221 Address after: 225500 No. 1 Su Zhong Road, Jiangyan, Jiangsu Patentee after: Jiangsu Suzhonghaixin Pharmaceutical Co.,Ltd. Address before: 710032 Changle West Road, Shaanxi, China, No. 17, No. Patentee before: Institute of Pharmaceuticals, Fourth Military Medical University |
|
| ASS | Succession or assignment of patent right |
Owner name: SZYY GROUP PHARMACEUTICAL LIMITED. Free format text: FORMER OWNER: JIANGSU SUZHONG HAIXIN PHARMACEUTICAL CO., LTD. Effective date: 20130806 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130806 Address after: 225500 No. 1 Su Zhong Road, Jiangyan District, Jiangsu, Taizhou Patentee after: JIANGSU SUZHONG PHARMACEUTICAL GROUP Co.,Ltd. Address before: 225500 No. 1 Su Zhong Road, Jiangyan, Jiangsu Patentee before: Jiangsu Suzhonghaixin Pharmaceutical Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: No.1 Suzhong Road, Jiangyan District, Taizhou City, Jiangsu Province 225500 Patentee after: Suzhong Pharmaceutical Group Co.,Ltd. Address before: No.1 Suzhong Road, Jiangyan District, Taizhou City, Jiangsu Province 225500 Patentee before: JIANGSU SUZHONG PHARMACEUTICAL GROUP Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |